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We report on a predictive model of long-term outcome in 114 high-risk breast cancer patients treated with high-dose
chemotherapy between 1989 and 1994. Parafﬁn-blocks from 90 of the 114 primaries were assessed for the presence of ﬁve
risk factors: grade, mitotic index, protein expression of p53, HER2/neu, and oestrogen/progesterone receptor status; we could
analyse the effect of risk factors in 84 of these 90 tumours. Seven-year relapse-free and overall survival was 58% (95%
conﬁdence interval 44–74%) and 82% (95% conﬁdence interval 71–94%) vs 33% (95% conﬁdence interval 21–52%) and
41% (95% conﬁdence interval 28–60%) for patients whose primary tumours displayed 53 risk factors vs patients with 42
risk factors. For the entire group of 168 high-risk breast cancer patients, inﬂammatory stage IIIB disease and involved post-
mastectomy margins were associated with decreased relapse-free survival and overall survival; patients treated with non-
doxorubicin containing standard adjuvant therapy experienced worse overall survival (RR, 2.08; 95% conﬁdence interval 1.04
to 4.16; P=0.04), while adjuvant tamoxifen improved overall survival (RR, 0.65; 95% conﬁdence interval 0.41–1.01; P=0.054).
Future trial designs and patient selection for studies speciﬁc for high-risk breast cancer patients should include appropriate
prognostic models. Validation of such models could come from recently completed randomised, prospective trials.
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Approximately 50% of patients with high-risk primary breast
cancer (HRBC), deﬁned by the presence of 510 involved axillary
lymph nodes, T3N1, T3N2, or inﬂammatory primary tumours are
likely to relapse within 3–5 years from the time of diagnosis
(Buzdar et al, 1992; Bonadonna et al, 1995; Moon et al, 1997;
Curcio et al, 1999). Improvements in relapse-free (RFS) and over-
all survival (OS) for these women with HRBC have been modest
(Hortobagyi et al, 1996). Although newer agents like the taxanes
have recently been evaluated as components of standard dose
adjuvant therapy, patients with HRBC remain at great risk of
relapse.
In 1997, we reported encouraging preliminary RFS and OS rates
in a cohort of 114 patients with HRBC treated with conventional
dose adjuvant therapy followed by high-dose chemotherapy
(HDCT) with either doxorubicin, etoposide, and cyclophospha-
mide (CAVP), (Somlo et al, 1994a) or cisplatin, etoposide, and
cyclophosphamide (CCVP) (Somlo et al, 1994b, 1997). Not all
patients beneﬁted equally; lack of progesterone receptor (PR)
expression on the primary tumour was identiﬁed as an adverse
predictor of outcome. In the current study, we set out to identify
additional tumour and treatment-associated predictors of RFS and
OS. Here, we report on the effect of stage, grade, mitotic index,
and immunohistochemically detectable parameters (p53, HER2/
neu, oestrogen and progesterone receptor status) on the outcome
of a 90 patient subset of this well-deﬁned, high-risk population
of 114 patients, whose parafﬁn-embedded primary tumours were
available for detailed analysis. Tumour and treatment-associated
prognostic indicators of RFS and OS were also assessed and
compared to a ‘standard’ cohort of concurrently-treated HRBC
patients who had received conventional adjuvant therapy only.
PATIENTS AND METHODS
All 114 patients participating in HDCT trials at the City of Hope
and treated between 1989 and 1994 gave their written, voluntary
informed consent for the study; patients with HRBC (stage II with
510 involved axillary nodes, stage IIIA or B) were 465-years old,
with a Karnofsky performance status of 580%. Patients with
conventional adjuvant doxorubicin exposure of 5150 mg m
72
and/or with prior left sided chest wall radiation received CCVP
(n=57); all others received CAVP (n=57). Details of the two HDCT
regimens, supportive care, and treatment-related toxicities have
been reported earlier (Somlo et al, 1997). Patients were intended
to receive radiation to the primary site/chest wall and draining
lymph node areas according to community standards. Patients with
either oestrogen (ER) and/or PR positive breast cancer were to
receive tamoxifen.
We performed a retrospective chart review of patients with
HRBC who received conventional adjuvant therapy only, between
the years 1989 and 1994. After obtaining approval by the Institu-
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meeting our deﬁnition of ‘high-risk’ were identiﬁed in our institu-
tional tumour registry. Patients in the standard group underwent
physical examinations and routine laboratory and radiographic
evaluations according to prevailing standards of clinical practice.
Of 213 HRBC cancer patients treated at our centre between 1989
and 1994 with standard chemotherapy, we could include 54 in this
analysis. Reasons for exclusion from the ‘standard’ group included
incomplete information on the pathology of the primary, treat-
ment, age 465 years, or participation on a competing dose-
intense protocol of doxorubicin, cyclophosphamide, and G-CSF
support (Morgan et al, 1997); the median time from diagnosis to
HDCT for patients in the HDCT group was 5.8 months; hence,
‘standard’ patients who relapsed within 6 months from diagnosis
were also excluded. Characteristics of patients in the HDCT and
standard treatment groups are shown in Table 1.
Post-treatment follow-up
Following HDCT, patients underwent physical examination at least
once every 4 months for the ﬁrst 3 years, and every 6 months
thereafter. Yearly mammograms, bone scans, and chest X-rays were
performed for the ﬁrst 3 years, with yearly mammograms continu-
ing thereafter. Patients in the ‘standard’ group were followed
according to prevailing clinical practice.
Histopathologic analysis
Representative sections from all primary tumours were reviewed
and analysed by a staff member of the Department of Anatomic
Pathology at the City of Hope National Medical Center. Special
features examined included grade, multifocality, receptor status,
and vascular invasion.
More detailed analysis by the same pathologist (J Simpson)
including assessment of combined histologic grade (Elston and Ellis,
1991; Dalton et al, 1994), mitotic index expressed as the number of
mitoses per 10 high power ﬁelds (HPF), vascular invasion, and
immunohistochemical features was performed on a subset of 90 of
the 114 HDCT-treated patients from whom parafﬁn blocks of the
primary tumour were available. The parafﬁn-embedded blocks were
dewaxed in xilene and rehydrated in ethanol; 4 mm sections were
placed on slides. Immunohistochemical stains were carried out
following microwave epitope retrieval. Slides were stained as single
batch using a Techmate 1000 immunostainer (Biotek solutions,
Santa Barbara, CA, USA). Clone DO7, Novocastra, Newcastle, UK,
was used at a 1:150 dilution to detect the presence of mutant
p53; a polyclonal antibody produced by Ciba-Corning, Alameda,
CA, USA, at 1:75 dilution, was used to detect expression of the
HER2/neu protein. Ki-67 was stained utilising MiB1 by Immuno-
tech, Mestbrook, ME, USA, at a 1:50 dilution; the antibodies 1D5
(Dako, Carpenteria, CA, USA; 1:60 dilution) and 1A6 (Novocastra,
Newcastle upon Tyne, UK; dilution 1:10) were applied to detect ER
and PR protein expression.
All primary antibody incubations were performed at room
temperature for 30 min. Biotin-labelled antimouse antibodies and
avidin-labelled peroxidase and diaminobenzidine detection system
were used for antigen localisation (Biotek ChemMate reagents).
Haematoxylin was used to counterstain the nucleus. Multi-tissue
blocks were used for positive and negative controls.
Immunohistochemical scoring for p53, ER, PR, and Ki67 was
considered positive based on the presence of diaminobenzipidine
precipitation observed at 1006magniﬁcation. The percentage of
stained nuclei was estimated, and the presence of 45% of cells
showing nuclear staining was considered positive. For Her-2/neu,
positive immunoreactivity was scored when diaminobenzipidine
precipitation was observed as crisp membraneous staining; positive
interpretation required staining of 45% of tumour cells. Intensity
score was assessed using a scale of I to III.
Statistical methods
Overall survival (OS) and relapse-free survival (RFS) were calcu-
lated from diagnosis. RFS was deﬁned as time to any type of
recurrence or death from any cause.
Univariate and multivariate Cox regression analyses were carried
out to assess potential predictors (inherent to the primary
tumours) and prognostic indicators (treatment-related variables)
of RFS and OS such as stage, size (42c m vs 42 cm and
45c mvs 45 cm), grade (high vs low and intermediate), multifo-
cality (unifocal vs multifocal), presence of vascular invasion (yes vs
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Table 1 Characteristics of all patients with high-risk breast cancer
HDCT group (n=114)
a Standard group (n=54)
Median (range) Median (range)
Follow-up time
b (months) 93 (54–144) 86 (64–118)
Age (years) 44 (26–61) 50 (29–65)
No. of axillary nodes involved 13 (0–42) 12 (0–34)
No. of standard adjuvant chemotherapy 4 (2–14) 4 (2–14)
cycles received
N (%)
Stage II 40 (35) 22 (41)
IIIA 51 (45) 19 (35)
IIIB 23 (20) 13 (24)
42 cm tumour 87 (76) 44 (81)
Tumour grade: high 62 (55) 33 (61)
Unknown 6 (5) 10 (19)
ER or PR: positive 75 (66) 34 (63)
Unknown 2 (2) 4 (7)
Treated with modiﬁed radical mastectomy 88 (77) 47 (87)
Margin post mastectomy: involved 12 (10) 2 (4)
Unknown 1 (1) 5 (9)
Received doxorubicin (Dox) as part of
standard adjuvant therapy 109 (96) 45 (80)
Treated with tamoxifen 54 (47) 23 (43)
Received local-regional radiation therapy 82 (72) 39 (72)
aTreated with CCVP (n=57) and CAVP (n=57).
bTime from diagnosis to last contact for live patients.
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510), Treatment-related prognostic factors included the type
(doxorubicin-containing: yes vs no) and number of cycles of adju-
vant therapy, administration of tamoxifen, and radiation treatment
to the primary site (yes vs no). As previously reported, no signiﬁ-
cant interactions between the two HDCT regimens (CAVP vs
CCVP) and each of the tested parameters were found (Somlo et
al, 1997); thus, the current analysis was carried out pooling the
patients treated with either of the two HDCT regimens.
For the subset of patients whose primary tumour blocks were
available, mitotic activity (43 out of 10 high power ﬁeld vs 43
out of 10 high power ﬁeld), and immunohistochemical detection
of nuclear staining (45% vs 45%) for p53, ER, PR, and Ki67
(by MIB-1), and membranous staining of 45% vs 45% for
HER2/neu, were analysed. Staining intensity was also analysed
grouping intensity levels of 0 and I vs II and III.
Standard Kaplan–Meier (Kaplan and Meier, 1958) and Cox (Cox,
1972) regression methods were applied for survival analysis using the
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l Table 2 Morphologic and immunohistochemical analysis of the primary tumours from 90 patients with high-risk breast
cancer treated with HDCT
Tumour grade n (%)
I–II (low-intermediate) 44 (49)
III (high-grade) 45 (50)
missing 1 (1)
Lymphatic invasion
None 43 (48)
Present 47 (52)
Mitotic activity/10 HPF
a
43 27 (30)
43 62 (69)
missing 1 (1)
Immunohistochemical
b Staining
staining n (%) intensity grading n (%)
MIB-1 MIB-1
45 31 (34) 0–I 21 (23)
45 57 (64) 5II 67 (75)
missing 2 (2) missing 2 (2)
P53 P53
45 65 (72) 0–I 48 (53)
45 23 (26) 5II 40 (45)
missing 2 (2) missing 2 (2)
ER ER
45 47 (52) 0–I 48 (53)
45 41 (46) 5II 40 (45)
missing 2 (2) missing 2 (2)
PR P53
45 48 (53) 0–I 45 (50)
45 40 (45) 5II 43 (45)
missing 2 (2) missing 2 (2)
HER2/neu P53
45 57 (63) 0–I 55 (61)
45 31 (35) 5II 33 (37)
missing 2 (2) missing 2 (2)
aHigh power ﬁeld.
bPercentage of cells stained.
Table 3 Univariate analysis of the affect of predictive risk factors on relapse-free and overall survival in the subset of 90 patients treated with HDCT
Overall Relapse-free
survival survival
Risk factor RR 95% CI P-value RR 95% CI P-value
45% p53 staining 2.9 1.51, 5.58 0.001 2.2 1.22, 3.99 0.01
45% HER2/neu staining 1.83 0.96, 3.49 0.06 1.81 1.03, 3.18 0.04
Stage IIIB 2.11 1.04, 4.28 0.03 1.88 0.98, 3.61 0.054
ER staining 0.64 0.33, 1.24 0.19 0.74 0.42, 1.31 0.30
PR staining 0.51 0.26, 0.995 0.044 0.53 0.30, 0.95 0.03
ER intensity 0.44 0.22, 0.87 0.02 0.49 0.28, 0.88 0.02
PR intensity 0.57 0.30, 1.1 0.09 0.50 0.28, 0.89 0.02
High-grade 2.05 1.04, 4.05 0.035 1.38 0.78, 2.44 0.27
High mitotic activity 3.47 1.35, 8.92 0.01 1.71 0.87, 3.36 0.11
Positive margins 3.1 1.39, 6.74 0.00 2.50 1.17, 5.34 0.01
Adjuvant therapy without doxorubicin 6.59 2.30, 18.88 50.001 5.74 2.00, 16.42 50.001
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 281–288SAS/STAT (SAS Institute, 2000) and S-Plus software. All signiﬁcance
testing was two-sided (log-rank statistics and Wald statistics were
used in univariate and multivariate analysis, respectively).
RESULTS
Predictive value of histopathologic analysis in patients
treated with HDCT
There was no difference in the characteristics of the entire 114
patient HDCT cohort and the 90 patient subset whose parafﬁn-
embedded tumour blocks were procured for analysis (data not
shown). Table 2 describes the histopathologic ﬁndings of the
tumour specimens from the 90 patients treated with HDCT. The
majority of tumours (69%) were characterised by increased mitotic
activity; half of the tumours were classiﬁed as high-grade and 52%
contained features of vascular invasion. The proliferative marker
Ki67 (as stained by MIB-1) was observed in 64% and staining
intensity was high (5grade II) in 75% of tumour specimens.
Either ER or PR positivity only, or both, was seen in 58% of the
tumours. High staining intensity (5II) for ER or PR was observed
in 45 and 48% of cases, respectively. Expression of p53 protein was
seen in 26% of tumours; 5grade II intensity of staining was
observed in 45% of tumours examined. Finally, 35% of tumours
overexpressed HER2/neu; 5grade II staining intensity was seen
in 37% of breast tumours.
Variables associated with an increased risk of relapse by univari-
ate analysis in the 90 HDCT-treated patients included the presence
of p53, overexpression of HER2/neu, and stage IIIB inﬂammatory
disease; PR positivity and ER staining at 5grade II intensity were
associated with a reduced risk of relapse (Table 3). OS was
adversely affected by the presence of p53, high grade features,
increased mitotic activity, and inﬂammatory presentation (stage
IIIB), while overexpression of HER2/neu showed a trend
(P=0.06) toward predicting shorter survival. Treatment-associated
adverse prognostic indicators for both RFS and OS included
involved tumour margin following mastectomy and non-doxorubi-
cin containing standard adjuvant chemotherapy (preceding
HDCT). Multivariate stepwise Cox regression analysis revealed that
the presence of the p53 protein (RR, 2.06; 95% CI, 1.11–3.83;
P=0.02) and non-doxorubicin containing adjuvant chemotherapy
(RR, 5.85; 95% CI, 1.71–19.99; P50.01) were predictors of
increased risk for relapse, while intense PR staining was associated
with lower incidence of relapse (RR, 0.55; 95% CI, 0.31–0.997;
P=0.049). OS was adversely affected by the presence of p53, (RR,
2.15; 95% CI, 1.05–4.37; P=0.04), increased mitosis (RR, 3.6;
95% CI, 1.30–10.08; P=0.01), inﬂammatory presentation (RR,
2.14; 95% CI, 1.00 to 4.57; P=0.05), and non-doxorubicin adjuvant
chemotherapy (RR, 13.4; 95% CI, 3.54–50.74; P50.01).
Patients whose primary tumour blocks were analysed were
assigned to favourable and unfavourable groups based on the
number of adverse predictive risk features (determined to be signif-
icant by univariate analysis as shown in Table 3), to generate a
scoring system. In an attempt to rely on inherent biological char-
acteristics of the tumours, only the 86 patients treated with a
doxorubicin-containing adjuvant regimen prior to HDCT therapy
were to be analysed for outcome; two specimens from these
patients were inadequate for p53 and HER2/staining; hence, only
84 of the 90 patients with tumour blocks were included in this
subsequent analysis.
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Table 4 Distribution of risk factors: high grade tumour, high mitotic index, ER/PR negativity, HER2/neu over-
expression, and the presence of p53 protein in patients with high-risk stage breast cancer treated with HDCT
Number of High
adverse risk No. of High mitotic ER/PR HER2/neu P53
factors patients grade index negative positive positive
01 5 0 0 0 0 0
11 4 0 8 4 2 0
21 6 1 1 1 5 3 2 1
3 19 13 17 8 12 7
41 7 1 7 1 7 1 3 1 0 1 1
53 3 3 3 3 3
Total 84 44 60 31 29 22
Favourable group (n=45)
Unfavourable group (n=39)
P=0.006
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Figure 1 (A) Relapse-free survival in 84 HDCT patients displayed by the
number of pathologic risk factors (42 vs 53). (B) Overall survival in 84
HDCT patients displayed by the number of pathologic risk factors (42
vs 53).
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factors: high mitotic index, high grade tumour, ER/PR receptor
negativity, presence of p53 protein, and overexpression of HER2/
neu protein. The outcome of patients with tumours demonstrating
4two adverse features (favourable group) was compared to those
patients with 5three adverse features (unfavourable group). Figure
1 reveals a signiﬁcantly higher risk of relapse (RR: 2.23, 95%CI
1.23–4.04; P=0.006) and death (RR: 3.68, 95% CI 1.75–7.75,
P=0.0002) for patients in the unfavourable group, whose tumours
tended to be characterised by ER/PR negativity, expression of p53
and overexpression of HER2/neu.
Prognostic indicators of outcome in 168 patients with
high-risk breast cancer
As shown in Table 1, the characteristics of the entire cohort of
114 patients treated with HDCT and the 54 patients in the stan-
dard treatment group were similar, although a slightly higher
percentage of HDCT-treated patients received standard doxorubi-
cin containing adjuvant therapy and presented with low to
intermediate grade tumours. When evaluating the entire group
of 168 patients with HRBC, RFS was adversely affected by presen-
tation with stage IIIB inﬂammatory features (RR, 1.74; 95% CI,
1.11–2.72; P=0.01), and for patients with positive post-mastect-
omy margins (RR, 1.94; 95% CI, 1.04–3.65; P=0.03); OS was
shorter in patients with inﬂammatory disease (RR, 2.17; 95%
CI, 1.35–3.48; P=0.001), positive margins (RR, 2.37; 95% CI,
1.25–4.51; P=0.01), and following standard adjuvant chemother-
apy with a non-doxorubicin containing regimen (RR, 2.08; 95%
CI, 1.04–4.16; P=0.04). Administration of adjuvant tamoxifen
was associated with lower risk of death (RR, 0.65; 95% CI,
0.41–1.01; P=0.052).
Seven-year projected RFS for stage II, IIIA and IIIB disease are
49% (95% CI, 36–68%), 43% (95% CI, 31–59%), and 35%
(95% CI, 20–61%) following HDCT, vs 17% (95% CI, 5–50%),
44% (95% CI, 25–77%), and 15% (95 CI, 4–55%) with standard
adjuvant therapy. The projected 7-year RFS for patients treated
with HDCT for all stages is 43% (95% CI, 35–54%) vs 26%
(95% CI, 16–43%) for the 54 patients treated with standard adju-
vant therapy, as shown in Figure 2. The projected 7-year OS for the
entire group of patients treated with HDCT is 57% (95% CI, 48–
67%) and 48% (95% CI, 36–65%) for the 54 patients treated with
standard adjuvant therapy; OS for stage II, IIIA and IIIB disease is
64% (95% CI, 50–81%), 56% (95% CI, 43–72%), and 48% (95%
CI, 31–73%) after HDCT vs 47% (95% CI, 29–76%), 74% (95%
CI, 56–96%), and 15% (95 CI, 4–55%) after standard therapy as
depicted in Figure 3.
A trend toward lower risk of death (RR 0.66; 95% CI, 0.42–
1.04; P=0.08) and relapse (RR 0.69; 95% CI, 0.46–1.03; P=0.07)
was observed in the 114 patients treated with HDCT compared
to the 54 ‘standard’ patients. A similar analysis restricted to those
patients who received doxorubicin-based adjuvant therapy either
prior to HDCT (109 patients), or as their only adjuvant treatment
(45 patients), revealed improved outcome with HDCT for both OS
(RR 0.61; 95% CI, 0.38–0.99; P=0.05) and RFS (RR 0.63; 95% CI,
0.41–0.95; P=0.03; data not shown). When assessing the role of
HDCT, there was no signiﬁcant difference between patients treated
with either CAVP or CCVP.
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Figure 2 Relapse-free survival for stage II, IIIA and IIIB high-risk breast cancer patients treated with HDCT (solid lines) vs standard adjuvant therapy
(dotted lines).
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In addition to tumour size, receptor status, inﬂammatory features,
proliferative rate, and grade, HER2/neu overexpression and expres-
sion of p53 protein have recently been identiﬁed as prognostic
indicators in the treatment of standard risk breast (Muss et al,
1994; Paik et al, 1998; Thor et al, 1998; Paik et al, 2000). However,
relatively few studies of predictive factors in the setting of HDCT
for HRBC have been published. Candidates for HDCT constitute
over 10% of all newly diagnosed cases of primary breast cancer;
(Wood et al, 1994; Bonadonna et al, 1995) in our estimate, the 114
patients we treated with HDCT between 1989 and 1994 represented
0.5% of the potentially eligible patient population in Southern Cali-
fornia, our primary service area (Somlo et al, 1997). Hence, our
observations are deduced from a selected patient population.
We previously identiﬁed PR negativity as an independent
predictor for relapse (Somlo et al, 1997). Nieto et al (1999) gener-
ated a predictive model based on tumour size, receptor status, and
axillary nodal ratio; later they found HER2/neu overexpression
(using monoclonal CB11 antibody-staining) as an additional inde-
pendent predictor of RFS and OS primarily in an otherwise
‘favourable’ group of patients (Nieto et al, 2000). Using a polyclo-
nal antibody-directed immunohistochemical stain the incidence of
HER2/neu positive staining in our HRBC population was very
similar to that reported in patients with stage II breast cancer
(Thor et al, 1998) and to the selected, high risk population
reported by Bitran et al (1996), although slightly lower then in
the series by Nieto et al (1999). Since there is wide variation in
the type and speciﬁcity of available antibodies and retrieving tech-
niques, and the clinical signiﬁcance of utilizing one antibody vs
another is unclear (Ravdin et al, 1998), the predictive value of
HER-2/neu ampliﬁcation for choosing the optimal adjuvant ther-
apy needs further validation.
We deﬁned several factors which may, either independently or in
concert, mark cancers with a high proliferation rate. Hence, it is not
surprising that in univariate analysis the presence of p53 protein,
overexpression of HER2/neu, and markers of high mitotic index,
or de-differentiation (such as lack of expression of ER/PR) are all
associated with poor outcome. Of the prognostic indicators tested,
the persistence of tumour in the surgical margin, another adverse
feature, may also be considered as an indirect measure of size and
invasiveness. The established beneﬁt associated with doxorubicin
as standard adjuvant therapy is in agreement with the ﬁndings of
larger studies in standard risk breast cancer (Bonadonna et al, 1995).
In keeping with our earlier observation, progesterone receptor
status remained a predictor of RFS. However, multivariate Cox
regression analysis may be of limited use when determining the
biological role of individual markers due to their potential similarity
as multiple measures of tumour aggressiveness. For example, since
ER and PR staining and intensity are highly correlated, a model
may choose only one feature, i.e., PR intensity. Similarly, the adverse
predictive value associated with the presence of p53 expression may
mask the signiﬁcance of other markers of proliferation, such as Ki67.
Grade, mitotic rate, and receptor status remain important character-
istics of a predictive model for patients with HRBC. Even relatively
nonspeciﬁc, immunohistochemically derived information on the
degree of p53 expression and HER2/neu ampliﬁcation may add to
our ability to predict outcome. However, technical standardisation
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Figure 3 Overall survival for stage II, IIIA and IIIB high-risk breast cancer patients treated with HDCT (solid lines) vs standard adjuvant therapy (dotted
lines).
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cation of these two later molecular markers.
Positive margin, inﬂammatory features, and lack of doxorubicin
in the standard adjuvant regimen were conﬁrmed to be adverse
predictors of outcome for the entire cohort of 168 high-risk
patients as well as for the 90 patient subset; however, instead of
receptor-positivity for the tumour, tamoxifen therapy in the
post-chemotherapy setting became a favourable predictor of
outcome. Since only patients with ER and/or PR positive tumours
received tamoxifen, this substitute ﬁnding points out the potential
methodological problems when parameters with overlapping func-
tions and features are evaluated.
Treatment of patients with HRBC continues to be a challenge,
especially, since the recent attempts incorporating newer agents
such as taxol into the standard adjuvant regimens have proven
somewhat disappointing (Eifel et al, 2001). The number of patients
treated with HDCT has dramatically decreased from its peak
(Antman et al, 1997). Early expectations of a 25–30% survival
beneﬁt with HDCT over standard chemotherapy in patients with
high-risk breast cancer were overstated partly based on data gener-
ated by fraud (Weiss et al, 2000). Two small and underpowered
randomised studies could not conﬁrm the beneﬁt of adjuvant
HDCT due, in part, to unrealistic (425%) expectations of beneﬁt
(Rodenhuis et al, 1998; Hortobagyi et al, 2000). Data presented
from a phase III US study has suggested a decreased relapse rate,
but no effect on OS, because of unacceptably high treatment-
related mortality following HDCT (Peters et al, 2001).
Preliminary data from a phase III Dutch trial in patients with
54 involved axillary lymph nodes have suggested a 15% RFS
and 10% OS beneﬁt in the ﬁrst 284 patients treated with a combi-
nation of carboplatin/thiotepa, and cyclophosphamide STAMP-V
HDCT at 3-years, although these results have not yet been
conﬁrmed in all 885 study participants (Rodenhuis et al, 2000).
In a prospective, randomised French trial of standard vs HDCT,
RFS of 55% vs 71% was reported, favouring the HDCT arm at
3-years (Roche et al, 2001).
While one awaits maturation of data from these studies, as well
as the two other, completed randomised trials from the United
States, further clariﬁcation of predictors of poor risk is appropriate.
Better selection of patients for studies of future HDCT
programmes, as well as other investigational approaches for women
with HRBC, may be possible after validation of this and other
(Nieto et al, 1999) prognostic models.
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